Investment Plan Pillars

Production of pharmaceutical raw materials

In several European nations, the pandemic has resulted in serious shortages of pharmaceutical raw materials.

The shortage which still remains must be eliminated immediately in order to protect Europe from future threats.

DEMO responds to the need to produce pharmaceutical raw materials. We establish a new industrial sector by constructing four new production units in Tripoli’s Industrial Area, each with a capacity of 200 tons of raw material per year.

DEMO pioneers and decreases Europe’s reliance on other nations through these investments, while contributing to the self-sufficiency and adequacy of local pharmaceutical manufacturing to the maximum degree.

Finished Pharmaceutical Product Manufacturing

For the last 30 years, pharmaceutical production has shifted towards other countries, resulting in a significant trade deficit in pharmaceutical product manufacturing.

As one of Europe’s top producers for injectables, DEMO is here to cover a considerable part of this shortage. Our company has completed the construction of two manufacturing plants in Kryoneri (Attica Prefecture) spanning ​​6,000 sq. m. In addition, six pharmaceutical production units will be built at the new industrial complex in Tripoli’s Industrial Area (Arcadia Prefecture), offering a capacity of 250 million finished products per year.

With these investments, DEMO will be capable of manufacturing all of the existing pharmaceutical products and categories of injectables to meet Greece’s needs, as well as up to 20% of the needs of hospitals and clinics across Europe.

Biotechnology

The field of Biotechnology is bringing about fascinating developments in medicine, treatments, and healthcare, as new, effective medicines are being produced from extremely complex natural compounds, with a biological origin.

The tide is changing. Greece, and the Greek pharmaceutical industry are both part of these developments, and DEMO is leading the way with major investments in biotechnology.

  • We are building a prototype unit for the development of monoclonal antibodies
  • We are creating a contemporary Research and Development Center for biotechnology
  • We are starting research for three finished pharmaceutical products with monoclonal antibodies
  • We are establishing a Biotechnology Academy to train young scientists Biotechnology is becoming part of our lives.

Research and Development

We invest in research and offer motivation to young researchers to remain in Greece to continue their work.

We created a new R&D Center for the development of monoclonal antibodies in Thessaloniki (2,500 sq. m.) and one R&D center in for final products in Athens (1,500 sq. m.).

Our company will develop 20 new pharmaceutical products and five API annually, while more than 150 scientits from various fields will work on our promises.

The impact of our investments

DEMO’s Role in Restoring Pharmaceutical Production in Europe after the Pandemic.

Why – in many countries, especially in Europe – were there so many serious shortages of medicines, and long delays in the import of raw materials during the pandemic? Why didn’t Greece  face this issue, and how did DEMO play a leading role in this effort? Find out how how the experience of the pandemic led to the resumption of pharmaceutical production in Europe, and how we are taking the next steps.

Investment Plan 2020-2021: The Environment and Circular Economy

At DEMO, we believe that investments are not only in buildings, medical equipment, and production facilities. Respect for the environment and principles of the circular economy are also investments. That is why we aim at energy saving, material recycling, and having the smallest possible effect on the environment, in every action we take.

The Impact of DEMO’s Investment Plan on the Economy

DEMO’s Investment Plan is strengthening the Greek economy, creating 600 new direct and 7,700 indirect job positions, while contributing €1.3 billion to the country’s GDP. DEMO has become a pharmaceutical hub, and is bringing Biotechnological Pharmaceutical Production to Greece for the first time. This attracts young scientists and contributes dynamically to the country’s brain gain with fully-trained scientific staff.